Matthew L. Sherman
Deciphera Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
TGF-β signaling in diseases, Gastrointestinal Tumor Research and Treatment, Renal cell carcinoma treatment, Gastric Cancer Management and Outcomes, Acute Myeloid Leukemia Research
Most-Cited Works
- → Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma(2004)943 cited
- → Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse(2001)883 cited
- Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.(1997)
- Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.(1997)
- → Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes(2020)526 cited
- → Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence(2005)451 cited
- Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis.(1992)